Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer’s disease

References

• Sosa-OrtizALAcosta-CastilloIPrinceMJEpidemiology of dementias and Alzheimer’s diseaseArch Med Res201243860060823159715
   PubMed Web of Science ®Google Scholar
• ReitzCBrayneCMayeuxREpidemiology of Alzheimer diseaseNat Rev Neurol20117313715221304480
   PubMed Web of Science ®Google Scholar
• RussTCBattyGDHearnshawGFFentonCStarrJMGeographical variation in dementia: systematic review with meta-analysisInt J Epidemiol20124141012103222798662
   PubMed Web of Science ®Google Scholar
• KalariaRNMaestreGEArizagaRAlzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factorsLancet Neurol20087981282618667359
   PubMed Web of Science ®Google Scholar
• DaviglusMLBellCCBerrettiniWNational Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive declineAnn Intern Med2010153317618120547888
   PubMed Web of Science ®Google Scholar
• QuerfurthHWLaFerlaFMAlzheimer’s diseaseN Engl J Med2010362432934420107219
   PubMed Web of Science ®Google Scholar
• MorrisJCEarly-stage and preclinical Alzheimer diseaseAlzheimer Dis Associ Disord2005193163165
   PubMed Web of Science ®Google Scholar
• SperlingRAAisenPSBeckettLAToward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimers Dement20117328029221514248
   PubMed Web of Science ®Google Scholar
• BirksJCholinesterase inhibitors for Alzheimer’s diseaseCochrane Database Syst Rev20061CD00559316437532
   PubMed Web of Science ®Google Scholar
• BordjiKBecerril-OrtegaJBuissonASynapses, NMDA receptor activity and neuronal Abeta production in Alzheimer’s diseaseRev Neurosci201122328529421568789
   PubMed Web of Science ®Google Scholar
• HardinghamGEBadingHSynaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disordersNat Rev Neurosci2010111068269620842175
   PubMed Web of Science ®Google Scholar
• McShaneRAreosa SastreAMinakaranNMemantine for dementiaCochrane Database Sys Rev20062CD003154
   Web of Science ®Google Scholar
• MartinaMComasTMealingGASelective pharmacological modulation of pyramidal neurons and interneurons in the CA1 region of the rat hippocampusFront Pharmacol201342423493925
   PubMed Web of Science ®Google Scholar
• HartmannSMobiusHJTolerability of memantine in combination with cholinesterase inhibitors in dementia therapyInt Clin Psychopharmacol2003182818512598818
   PubMed Web of Science ®Google Scholar
• SchneiderLSInselPSWeiner MW; Alzheimer’s Disease NeuroimagingITreatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s Disease Neuroimaging InitiativeArch Neurol2011681586621220675
   PubMedGoogle Scholar
• AtriAShaughnessyLWLocascioJJGrowdonJHLong-term course and effectiveness of combination therapy in Alzheimer diseaseAlzheimer Dis Associ Disord2008223209221
   PubMed Web of Science ®Google Scholar
• LopezOLBeckerJTWahedASLong-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer diseaseJ Neurol Neurosurg Psychiatry200980660060719204022
   PubMed Web of Science ®Google Scholar
• PorsteinssonAPGrossbergGTMintzerJOlinJTMemantine MEM-MD-12 Study GroupMemantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trialCurr Alzheimer Res200851838918288936
   PubMed Web of Science ®Google Scholar
• TariotPNFarlowMRGrossbergGTMemantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trialJAMA2004291331732414734594
   PubMed Web of Science ®Google Scholar
• HowardRMcShaneRLindesayJDonepezil and memantine for moderate-to-severe Alzheimer’s diseaseN Engl J Med20123661089390322397651
   PubMed Web of Science ®Google Scholar
• MuayqilTCamicioliRSystematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer’s disease and other dementiasDement Geriat Cogn Disord Extra201221546572
   Google Scholar
• MorethJMavoungouCSchindowskiKPassive anti-amyloid immunotherapy in Alzheimer’s disease: What are the most promising targets?Immun Age201310118
   PubMed Web of Science ®Google Scholar
• RingmanJMCoppolaGNew genes and new insights from old genes: update on Alzheimer diseaseContinuum (Minneap Minn)2013192 Dementia35837123558482
   PubMedGoogle Scholar
• MangialascheFSolomonAWinbladBMecocciPKivipeltoMAlzheimer’s disease: clinical trials and drug developmentLancet Neurol20109770271620610346
   PubMed Web of Science ®Google Scholar
• MayPCDeanRALoweSLRobust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitorJ Neurosci20113146165071651622090477
   PubMed Web of Science ®Google Scholar
• MikulcaJANguyenVGajdosikDAPotential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approachesJ Clin Pharma Ther20143912537
   PubMed Web of Science ®Google Scholar
• Merck Sharp and Dohme CorpAn Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer’s Disease (P07738) (EPOCH)ClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated January 30, 2014]. Available from http://clinicaltrials.gov/show/NCT01739348. NLM identifier: NCT01739348Accessed February 2, 2014
   Google Scholar
• DoodyRSRamanRFarlowMSemagacestat Study GroupA phase 3 trial of semagacestat for treatment of Alzheimer’s diseaseN Engl J Med2013369434135023883379
   PubMed Web of Science ®Google Scholar
• FuHJLiuBFrostJLLemereCAAmyloid-beta immunotherapy for Alzheimer’s diseaseCNS Neurol Disord Drug Targets20109219720620205640
   PubMed Web of Science ®Google Scholar
• SperlingRSallowaySBrooksDJAmyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysisLancet Neurol201211324124922305802
   PubMed Web of Science ®Google Scholar
• MatthewsGBaderVIndependent analysis of solanezumab provides evidence that compound may remove amyloid from brain in Alzheimer’s disease [webpage on the Internet]Monaco10292012 Available from: http://www.fiercebiotech.com/press-releases/independent-analysis-solanezumab-provides-evidence-compound-may-remove-amylAccessed January 22, 2014
   Google Scholar
• OstrowitzkiSDeptulaDThurfjellLMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumabArch Neurol201269219820721987394
   PubMedGoogle Scholar
• GenentechA Long-Term Safety Extension Study of Studies ABE4869g And ABE4955g in Patients With Mild To Moderate Alzheimer’s Disease Treated With CrenezumabClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated January 21, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01723826?term=NCT01723826&rank=1. NLM identifier: NCT01723826Accessed February 2, 2014
   Google Scholar
• LaPointeNEMorfiniGPiginoGThe amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicityJ Neurosci Res200987244045118798283
   PubMed Web of Science ®Google Scholar
• WangXSuBLeeHGImpaired balance of mitochondrial fission and fusion in Alzheimer’s diseaseJ Neurosci200929289090910319605646
   PubMed Web of Science ®Google Scholar
• RapoportMDawsonHNBinderLIVitekMPFerreiraATau is essential to beta-amyloid-induced neurotoxicityProc Nat Acad Sci U S A200299963646369
   PubMed Web of Science ®Google Scholar
• IttnerLMGotzJAmyloid-beta and tau – a toxic pas de deux in Alzheimer’s diseaseNat Rev Neurosci2011122657221193853
   PubMed Web of Science ®Google Scholar
• BraakHDel TrediciKThe pathological process underlying Alzheimer’s disease in individuals under thirtyActa Neuropathol2011121217118121170538
   PubMed Web of Science ®Google Scholar
• LiuLDrouetVWuJWTrans-synaptic spread of tau pathology in vivoPloS One201272e3130222312444
   PubMed Web of Science ®Google Scholar
• PriceJLMorrisJCTangles and plaques in nondemented aging and “preclinical” Alzheimer’s diseaseAnn Neurol199945335836810072051
   PubMed Web of Science ®Google Scholar
• JackCRJrKnopmanDSJagustWJTracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkersLancet Neurol201312220721623332364
   PubMed Web of Science ®Google Scholar
• MusiekESHoltzmanDMOrigins of Alzheimer’s disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvementCurr Opin Neurol201225671572023041958
   PubMed Web of Science ®Google Scholar
• PievaniMde HaanWWuTSeeleyWWFrisoniGBFunctional network disruption in the degenerative dementiasLancet Neurol201110982984321778116
   PubMed Web of Science ®Google Scholar
• YoshiyamaYLeeVMTrojanowskiJQTherapeutic strategies for tau mediated neurodegenerationJ Neurol Neurosurg Psychiatry201384778479523085937
   PubMed Web of Science ®Google Scholar
• WischikCMEdwardsPCLaiRYRothMHarringtonCRSelective inhibition of Alzheimer disease-like tau aggregation by phenothiazinesProc Nat Acad Sci U S A199693201121311218
   PubMed Web of Science ®Google Scholar
• OzMLorkeDEPetroianuGAMethylene blue and Alzheimer’s diseaseBiochem Pharmacol200978892793219433072
   PubMed Web of Science ®Google Scholar
• TauRx Therapeutics LtdSafety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer’s DiseaseClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated November 24, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01689246?term=NCT01689246&rank=1. NLM identifier: NCT01689246Accessed February 2, 2014
   Google Scholar
• ReddyPHReddyTPMitochondria as a therapeutic target for aging and neurodegenerative diseasesCurr Alzheimer Res20118439340921470101
   PubMed Web of Science ®Google Scholar
• GhoshSSSwerdlowRHMillerSWSheemanBParkerWDJrDavisREUse of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer’s disease and Parkinson’s diseaseAnn NY Acad Sci199989317619110672237
   PubMed Web of Science ®Google Scholar
• HauptmannSScherpingIDroseSMitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic miceNeurobiol Aging200930101574158618295378
   PubMed Web of Science ®Google Scholar
• RiceACKeeneyPMAlgarzaeNKLaddACThomasRRBennettJPJrMitochondrial DNA Copy Numbers in Pyramidal Neurons are Decreased and Mitochondrial Biogenesis Transcriptome Signaling is Disrupted in Alzheimer’s Disease HippocampiJ Alzheimers Dis1212014 [Epub ahead of print]
   Web of Science ®Google Scholar
• SwerdlowRHAlzheimer’s disease pathologic cascades: who comes first, what drives whatNeurotox Res201222318219421913048
   PubMed Web of Science ®Google Scholar
• EckertGPRennerKEckertSHMitochondrial dysfunction – a pharmacological target in Alzheimer’s diseaseMol Neurobiol201246113615022552779
   PubMed Web of Science ®Google Scholar
• SwerdlowRHBurnsJMKhanSMThe Alzheimer’s disease mitochondrial cascade hypothesisJ Alzheimers Dis201020Suppl 2S265S27920442494
   PubMed Web of Science ®Google Scholar
• DoodyRSGavrilovaSISanoMEffect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled studyLancet2008372963420721518640457
   PubMed Web of Science ®Google Scholar
• Dimebon Disappoints in Phase 3 Trial0432010 http://www.alzforum.org/news/research-news/dimebon-disappoints-phase-3-trial
   Google Scholar
• LermontovaNNRedkozubovAEShevtsovaEFSerkovaTPKireevaEGBachurinSODimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channelsBull Exp Biol Med200113251079108311865327
   PubMed Web of Science ®Google Scholar
• WuJLiQBezprozvannyIEvaluation of Dimebon in cellular model of Huntington’s diseaseMol Neurodegener200831518939977
   PubMed Web of Science ®Google Scholar
• GrigorevVVDranyiOABachurinSOComparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neuronsBull Exp Biol Med2003136547447714968164
   PubMed Web of Science ®Google Scholar
• BachurinSOShevtsovaEPKireevaEGOxenkrugGFSablinSOMitochondria as a target for neurotoxins and neuroprotective agentsAnn N Y Acad Sci2003993334344 discussion 345–33912853325
   PubMed Web of Science ®Google Scholar
• SteeleJWGandySLatrepirdine (Dimebon(R)), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse modelAutophagy20139461761823380933
   PubMed Web of Science ®Google Scholar
• Cano-CuencaNSolis-Garcia Del PozoJEJordanJEvidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysisJ Alzheimers Dis20143815516423948924
   PubMed Web of Science ®Google Scholar
• McGuinnessBO’HareJCraigDBullockRMaloufRPassmorePStatins for the treatment of dementiaCochrane Database Sys Revs20108CD007514
   Web of Science ®Google Scholar
• MaloufRGrimley EvansJThe effect of vitamin B6 on cognitionCochrane Database Sys Rev20034CD004393
   Google Scholar
• FarinaNIsaacMGClarkARRustedJTabetNVitamin E for Alzheimer’s dementia and mild cognitive impairmentCochrane Database Sys Revs201211CD002854
   PubMed Web of Science ®Google Scholar
• MaloufRGrimley EvansJFolic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented peopleCochrane Database Sys Revs20084CD004514
   Web of Science ®Google Scholar
• JanssenIMSturtzSSkipkaGZentnerAVelasco GarridoMBusseRGinkgo biloba in Alzheimer’s disease: a systematic reviewWien Med Wochenschr201016021–2253954621170694
   PubMedGoogle Scholar
• MaloufRAreosa SastreAVitamin B12 for cognitionCochrane Database Sys Revs20033CD004326
   Web of Science ®Google Scholar
• ConnellyPJPrenticeNPCouslandGBonhamJA randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer’s diseaseInt J Geriat Psychiatry2008232155160
   PubMed Web of Science ®Google Scholar
• AnnweilerCHerrmannFRFantinoBBruggBBeauchetOEffectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot studyCogn Behav Neurol201225312112722960436
   PubMed Web of Science ®Google Scholar
• AnnweilerCFantinoBParot-SchinkelEThierySGautierJBeauchetOAlzheimer’s disease – input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trialTrials20111223022014101
   PubMed Web of Science ®Google Scholar
• Garcia-OstaACuadrado-TejedorMGarcia-BarrosoCOyarzabalJFrancoRPhosphodiesterases as therapeutic targets for Alzheimer’s diseaseACS Chem Neurosci201231183284423173065
   PubMed Web of Science ®Google Scholar
• HiramatsuMTakiguchiONishiyamaAMoriHCilostazol prevents amyloid beta peptide(25–35)-induced memory impairment and oxidative stress in miceBr J Pharmacol201016181899191220825411
   PubMed Web of Science ®Google Scholar
• GongBVitoloOVTrincheseFLiuSShelanskiMArancioOPersistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatmentJ Clin Invest2004114111624163415578094
   PubMed Web of Science ®Google Scholar
• ChengYFWangCLinHBInhibition of phosphodiesterase-4 reverses memory deficits produced by Abeta25-35 or Abeta1-40 peptide in ratsPsychopharmacology2010212218119120640406
   PubMed Web of Science ®Google Scholar
• Cuadrado-TejedorMHerviasIRicobarazaASildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer’s diseaseBr J Pharmacol201116482029204121627640
   PubMed Web of Science ®Google Scholar
• SakuraiHHanyuHSatoTEffects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot studyGeriat Gerontol Int20131319097
   Web of Science ®Google Scholar
• Seoul National University HospitalCilostazol Augmentation Study in DementiaClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated August 3, 2011]. Available from http://clinicaltrials.gov/ct2/show/NCT01409564?term=NCT01409564&rank=1. NLM identifier: NCT01409564Accessed February 2, 2014
   Google Scholar
• LandrethGJiangQMandrekarSHenekaMPPARgamma agonists as therapeutics for the treatment of Alzheimer’s diseaseNeurotherapeutics20085348148918625459
   PubMed Web of Science ®Google Scholar
• GeldmacherDSFritschTMcClendonMJLandrethGA randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer diseaseArch Neurol2011681455020837824
   PubMedGoogle Scholar
• TakedaBiomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its OnsetClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2013 [updated November 11, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01931566?term=NCT01931566&rank=1. NLM identifier: NCT01931566Accessed February 2, 2014
   Google Scholar
• AlvarezXACacabelosRSampedroCCombination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezilCurr Alzheimer Res20118558359121679156
   PubMed Web of Science ®Google Scholar
• MandelRJCERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer’s diseaseCurr Opin Mol Ther201012224024720373268
   PubMed Web of Science ®Google Scholar
• CeregeneCERE-110 in Subjects With Mild to Moderate Alzheimer’s DiseaseClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2004 [updated June 30, 2010]. Available from http://clinicaltrials.gov/ct2/show/NCT00087789?term=NCT00087789&rank=1. NLM identifier: NCT00087789Accessed February 2, 2014
   Google Scholar
• GeldenhuysWJVan der SchyfCJSerotonin 5-HT6 receptor antagonists for the treatment of Alzheimer’s diseaseCurr Top Med Chem20088121035104818691131
   PubMed Web of Science ®Google Scholar
• Maher-EdwardsGZvartau-HindMHunterAJDouble-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s diseaseCurr Alzheimer Res20107537438520043816
   PubMed Web of Science ®Google Scholar
• H. Lundbeck A/SStudy of Lu AE58054 in Patients With Mild - Moderate Alzheimer’s Disease Treated With Donepezil (STARSHINE)ClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2013 [updated October 10, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01955161?term=NCT01955161&rank=1. NLM identifier: NCT01955161Accessed February 2, 2014
   Google Scholar
• WagnerTValero-CabreAPascual-LeoneANoninvasive human brain stimulationAnn Rev Biomed Eng2007952756517444810
   PubMed Web of Science ®Google Scholar
• FreitasCMondragon-LlorcaHPascual-LeoneANoninvasive brain stimulation in Alzheimer’s disease: systematic review and perspectives for the futureExp Gerontol201146861162721511025
   PubMed Web of Science ®Google Scholar
• HoogendamJMRamakersGMDi LazzaroVPhysiology of repetitive transcranial magnetic stimulation of the human brainBrain Stimul2010329511820633438
   PubMed Web of Science ®Google Scholar
• GuseBFalkaiPWobrockTCognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic reviewJ Neural Transm2010117110512219859782
   PubMed Web of Science ®Google Scholar
• BohningDEShastriAWassermannEMBOLD-f MRI response to single-pulse transcranial magnetic stimulation (TMS)J Magnetic Resonance Image2000116569574
   Web of Science ®Google Scholar
• Sole-PadullesCBartres-FazDJunqueCRepetitive transcranial magnetic stimulation effects on brain function and cognition among elders with memory dysfunction. A randomized sham-controlled studyCereb Cortex200616101487149316339086
   PubMed Web of Science ®Google Scholar
• CotelliMManentiRCappaSFEffect of transcranial magnetic stimulation on action naming in patients with Alzheimer diseaseArch Neurol200663111602160417101829
   PubMed Web of Science ®Google Scholar
• CotelliMManentiRCappaSFZanettiOMiniussiCTranscranial magnetic stimulation improves naming in Alzheimer disease patients at different stages of cognitive declineEuro J Neurol2008151212861292
   PubMed Web of Science ®Google Scholar
• CotelliMCalabriaMManentiRImproved language performance in Alzheimer disease following brain stimulationJ Neurol Neurosurg Psychiatry201182779479720574108
   PubMed Web of Science ®Google Scholar
• AhmedMADarwishESKhedrEMEl SerogyYMAliAMEffects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer’s dementiaJ Neurol20122591839221671144
   PubMed Web of Science ®Google Scholar
• SitzerDITwamleyEWJesteDVCognitive training in Alzheimer’s disease: a meta-analysis of the literatureActa Psychiatr Scand20061142759016836595
   PubMed Web of Science ®Google Scholar
• Bahar-FuchsAClareLWoodsBCognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementiaCochrane Database Sys Rev20136CD003260
   Google Scholar
• BentwichJDobronevskyEAichenbaumSBeneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer’s disease: a proof of concept studyJ Neural Transm2011118346347121246222
   PubMed Web of Science ®Google Scholar
• Beth Israel Deaconess Medical CenterEffects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer PatientsClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated September 9, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01504958?term=NCT01504958&rank=1. NLM identifier: NCT01504958Accessed February 2, 2104
   Google Scholar
• BatemanRJXiongCBenzingerTLClinical and biomarker changes in dominantly inherited Alzheimer’s diseaseN Engl J Med2012367979580422784036
   PubMed Web of Science ®Google Scholar
• BatemanRJAisenPSDe StrooperBAutosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s diseaseAlzheimers Res Ther201131121211070
   PubMed Web of Science ®Google Scholar
• MorrisJCAisenPSBatemanRJDeveloping an international network for Alzheimer research: The Dominantly Inherited Alzheimer NetworkClin Invest2012210975984
   PubMedGoogle Scholar
• ReimanEMLangbaumJBFleisherASAlzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatmentsJ Alzheimers Dis201126Suppl 332132921971471
   PubMed Web of Science ®Google Scholar
• MillerGAlzheimer’s research. Stopping Alzheimer’s before it startsScience2012337609679079222903991
   PubMed Web of Science ®Google Scholar